Please use this identifier to cite or link to this item: http://ir.mu.ac.ke:8080/jspui/handle/123456789/10498
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKilach, C.-
dc.contributor.authorNjuguna, F.-
dc.contributor.authorGreist, A.-
dc.contributor.authorNjuguna, C.-
dc.contributor.authorMidiwo, Nancy-
dc.contributor.authorOburah, E.-
dc.contributor.authorAliwa, E.-
dc.contributor.authorKorir, R.-
dc.contributor.authorBor, C.-
dc.date.accessioned2026-09-10T08:43:48Z-
dc.date.available2026-09-10T08:43:48Z-
dc.date.issued2022-
dc.identifier.urihttps://www.postersessiononline.eu/173580348_eu/congresos/WFH2022/aula/-PP_64_WFH2022.pdf-
dc.identifier.urihttp://ir.mu.ac.ke:8080/jspui/handle/123456789/10498-
dc.description.abstractProphylactic treatment for Persons with Hemophilia (PWH) still remains largely inaccessible in Kenya. Donation of Emicizumab for PWH A through the World Federation of Hemophilia (WFH) Humanitarian Aid Programme in March 2021, started the first sustainable prophylaxis programme in Kenya.en_US
dc.language.isoenen_US
dc.subjectBleeding ratesen_US
dc.subjectHemophiliaen_US
dc.titleImpact of Emicizumab on annualized bleeding rates in persons with haemophilia A in Western Kenyaen_US
dc.typeArticleen_US
Appears in Collections:School of Medicine

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.